UK markets close in 1 hour 59 minutes

VITA 34 AG (0NLV.L)

LSE - LSE Delayed price. Currency in EUR
Add to watchlist
12.950.00 (0.00%)
As of 3:13PM GMT. Market open.
Full screen
Previous close12.95
Open12.95
Bid0.00 x N/A
Ask0.00 x N/A
Day's range12.95 - 12.95
52-week range12.95 - 12.95
Volume104
Avg. volumeN/A
Market capN/A
Beta (5Y monthly)1.21
PE ratio (TTM)35.09
EPS (TTM)0.37
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Introducing Constellation Brands (NYSE:STZ), A Stock That Climbed 57% In The Last Five Years
    Simply Wall St.

    Introducing Constellation Brands (NYSE:STZ), A Stock That Climbed 57% In The Last Five Years

    If you buy and hold a stock for many years, you'd hope to be making a profit. Furthermore, you'd generally like to see...

  • EQS Group

    Vita 34 manages crisis environment well with a strong third quarter

    DGAP-News: Vita 34 AG / Key word(s): 9 Month figures12.11.2020 / 07:30 The issuer is solely responsible for the content of this announcement.Vita 34 manages crisis environment well with a strong third quarter Revenues after nine months of EUR 15.0 million almost at previous year's level EBITDA margin of 29.1 percent despite increased marketing expenses, close to the target of 30 percent Increased demand for new PUR price model leads to steady increase in recurring salesLeipzig, 12 November 2020 - Vita 34 AG (ISIN: DE000A0BL849; WKN: A0BL84), one of the largest cell banks in Europe, continues to perform very well in the economic environment shaped by the COVID 19 pandemic. In particular, strong growth in new business in the core market Germany led to a return to the growth path and a significant improvement in sales development compared to the second quarter. Even year-on-year, the slightly weaker start to 2020 was almost completely made up for by the end of the third quarter. For the year-end business there are also signs of a consistently positive business performance without any major pandemic effects.At EUR 15.0 million, revenues for the first nine months were only 0.6 percent down on the previous year (9M 2019: EUR 15.1 million). Demand for the new PUR price model increased significantly, as the company has also been offering the storage of umbilical cord tissue via this contractual model since April 2020. Since then, the proportion of contracts concluded with tissue storage has increased significantly, resulting in an increase in sales per contract. The product, which is designed as an annual payer model, thus has an additional positive effect on the cash flow from storage fees. Earnings before interest, taxes, depreciation and amortization (EBITDA) were only 3.8 percent lower at EUR 4.4 million (9M 2019: EUR 4.5 million), although the company continued to invest heavily in marketing measures. First and foremost, the company intensified its efforts to address gynecologists and midwives as two of its most important target groups and further pushed the online marketing of its products. Accordingly, the EBITDA margin remained at a high level of 29.1, close to the target margin of 30 percent."We can be very satisfied with the course of the third quarter, as the increased demand for our PUR product is leading above all to rising recurring revenues," explains Dr. Wolfgang Knirsch, CEO of Vita 34 AG. "Although this means that cash flows from our new business are also shifting into the future, it also promotes our future business development. This is a highly desirable development for us, even if it is reflected in a declining operating cash flow in the short term."The key figures on business development are as follows: in EUR '000 Q3 2020 Q3 2019 9M 2020 9M 2019 ∆ H1 Revenues 5,424 5,351 15,024 15,119 -0.6% Gross profit 3,391 3,472 9,139 9,487 -3.7% EBITDA 1,761 1,753 4,368 4,542 -3.8% EBITDA margin [%] 32.5% 32.8% 29.1% 30.0% -3.2% EBIT 1,140 1,137 2,528 2,697 -6.3% Net earnings 750 173 1,860 1,220 52.4% Earnings per share 0.18 0.04 0.45 0.30 50.0% Operating cash flow -- -- 3,125 4,627 -32.4% Cash & cash equivalents (vs. year-end 2019) -- -- 10,519 9,102 15.6% The Management Board continues to assess the impact of the COVID 19 pandemic on the course of business as low overall. Although a regional analysis still shows that the southern European countries, which are more severely affected by the pandemic, are lagging behind expectations in terms of the number of storages. In the core markets of the DACH region, however, business development continues to be solid and at best with very little impact from the pandemic. Nevertheless, the company has taken precautions for a possible worsening of the situation in the course of a second wave of the pandemic and is maintaining a high level of inventories of production-related precursors. Despite the resulting further increase in working capital requirements, cash and cash equivalents increased further and amounted to EUR 10.5 million at the end of September (31.12.2019: EUR 9.1 million).The development of new future and development projects, such as the storage of immune cells from peripheral blood of adults and the storage of fat cells for use in aesthetic medicine ("AdipoVita"), is progressing according to plan despite pandemic-related restrictions. For AdipoVita, the company recently received the manufacturing license for the Leipzig site and is now establishing distribution partnerships."Against the background of the course of business to date and the current order situation for the fourth quarter, we continue to feel very comfortable with our guidance for the year as a whole and are reiterating it accordingly," commented Falk Neukirch, CFO of Vita 34. "Given the long lead times between the conclusion of contracts and the realization of sales, we also do not expect a second wave of the pandemic to have any negative impact here."For the full year 2020, the Managhement Board therefore continues to expect revenues of between EUR 19.0 and 21.0 million and EBITDA of between EUR 4.8 and 5.8 million.Contact:Ingo MiddelmenneInvestor RelationsVita 34 AGPhone: +49 (0341) 48792 - 0Mobile: +49 (0174) 9091190Email: ingo.middelmenne@vita34.deCompany profileVita 34 was founded in Leipzig in 1997 and is today one of the leading cell banks in Europe. As the first private umbilical cord blood bank in Europe and a pioneer in cell banking, the company has been offering collection logistics, preparation and storage of stem cells from umbilical cord blood and umbilical cord tissue as a full-service provider for cryopreservation ever since. Based on the expansion of the business model in 2019, Vita 34 also intends to offer the storage of immune cells from peripheral blood and stem cells from the body's own fat in the future. The body's own cells are a valuable starting material for medical cell therapy and are kept alive at temperatures around minus 200 degrees Celsius so that they can be used for treatment if necessary. More than 237,000 customers from more than 20 countries have already provided for the health of their families with a cell depot at Vita 34.12.11.2020 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de Language: English Company: Vita 34 AG Deutscher Platz 5a 04103 Leipzig Germany Phone: +49(0341)48792-40 Fax: +49(0341)48792-39 E-mail: ir@vita34.de Internet: www.vita34.de ISIN: DE000A0BL849 WKN: A0BL84 Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange EQS News ID: 1147187   End of News DGAP News Service

  • EQS Group

    Business development of Vita 34 gains significant momentum again in the second quarter

    DGAP-News: Vita 34 AG / Key word(s): Half Year Results 27.08.2020 / 07:30 The issuer is solely responsible for the content of this announcement. Business development of Vita 34 gains significant momentum again in the second quarter * Revenues up again significantly compared with the previous quarter * EBITDA margin increases to 29.3 percent in the second quarter * Good cash flow development allows cash and cash equivalents to rise significantly to EUR 9.9 million Leipzig, 27 August 2020 \- The business development of Vita 34 AG (ISIN: DE000A0BL849; WKN: A0BL84), one of the largest cell banks in Europe, has largely returned to normal despite the adverse economic environment. Compared to the weaker start to the year, revenues increased significantly in the second quarter, with a simultaneous recovery of the EBITDA margin to 29.3 percent. Overall, the market environment began to brighten up at the beginning of the second quarter, which is reflected in an increase in stored units, particularly at the end of the second quarter, and a sustained increase in incoming orders. Compared with the previous year, revenues in the first half of the year were down by only 1.7 percent to EUR 9.6 million (H1 2019: EUR 9.8 million). Earnings before interest, taxes, depreciation and amortization (EBITDA) of EUR 2.6 million in the first half of the year were slightly lower than in the same period last year (H1 2019: EUR 2.8 million) due to the sales trend as well as higher marketing and sales expenses, especially in the first quarter. In the second quarter, the company returned to the previous year's level with an EBITDA of EUR 1.4 million and an EBITDA margin of 29.3 percent, despite one-off extraordinary expenses in connection with the takeover bid. "All in all, it is clear that COVID-19 has at times hindered the marketing opportunities of our product range and thus has not left Vita 34 unaffected," explains Dr. Wolfgang Knirsch, CEO of Vita 34 AG. "However, we have adapted to the new circumstances and have thus succeeded in quickly picking up speed again even in this changed environment. In particular through optimized online marketing and web-based events, we are able to convince parents-to-be of our offer even more directly and personally than before." The key figures for the business development are as follows:in EUR '000 Q2 2020 Q2 2019 H1 2020 H1 2019 ∆ H1 Revenues 4,927 4,983 9,600 9,768 -1.7% Gross profit 2,979 3,126 5,749 6,015 -4.4% EBITDA 1,442 1,497 2,607 2,789 -6.5% EBITDA margin [%] 29.3 30.0 27.2 28.6 -4.9% EBIT 833 883 1,388 1,560 -11.0% Net earnings 741 586 1,109 1,048 5.9% Earnings per share 0.18 0.14 0.27 0.26 3.8% Operating cash flow \-- \-- 1,842 2,359 -21.9% Cash & cash equivalents (vs. 31.12.2019) \-- \-- 9,938 9,102 9.2% The limited but noticeable impact of the COVID-19 pandemic on the course of business becomes apparent when looking at the regional development of sales. While there was almost no clouding of business in the core markets of the DACH region, this was more evident in the regions in Southern Europe that were more strongly influenced by COVID-19. Thanks to the good earnings performance, Vita 34 was able to generate an operating cash flow of EUR 1.8 million in the first half of 2020, which was below the previous year's figure of EUR 2.4 million, but nevertheless underlines the company's high internal financing power. The main reasons for the decline were higher stockpiling as a precautionary measure in the wake of the COVID-19 pandemic, increased receivables due to the new PUR contract model and higher income tax payments due to the profitability achieved. The cash flow from investing and financing activities also developed positively, resulting in a further overall increase in cash & cash equivalents of 9.2 percent to EUR 9.9 million (31.12.2019: EUR 9.1 million). "The second quarter shows us that we are coping well with the current situation," says CFO Falk Neukirch confidently. "Our business performance is good, as the circumstances dictate, and our finances remain extremely sound. We are still on schedule with the development of the immune cell product, although the general environment in the current phase of partner search limits the possibilities for intensive talks." Against the background of the good development in the first half of the year and the course of business in the third quarter so far, the Management Board confirms the outlook for the full year 2020. Accordingly, revenues of between EUR 19.0 and 21.0 million and EBITDA of between EUR 4.8 and 5.8 million are still anticipated. Contact: Ingo Middelmenne Investor Relations Vita 34 AG Phone: +49 (0341) 48792 - 0 Mobile: +49 (0174) 9091190 Email: ingo.middelmenne@vita34.de Company profile Vita 34 was founded in Leipzig in 1997 and is today one of the leading cell banks in Europe. As the first private umbilical cord blood bank in Europe and a pioneer in cell banking, the company has been offering collection logistics, preparation and storage of stem cells from umbilical cord blood and umbilical cord tissue as a full-service provider for cryopreservation ever since. Based on the expansion of the business model in 2019, Vita 34 also intends to offer the storage of immune cells from peripheral blood and stem cells from the body's own fat in the future. The body's own cells are a valuable starting material for medical cell therapy and are kept alive at temperatures around minus 200 degrees Celsius so that they can be used for treatment if necessary. More than 237,000 customers from more than 20 countries have already provided for the health of their families with a cell depot at Vita 34. * * *27.08.2020 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de * * * Language: English Company: Vita 34 AG Deutscher Platz 5a 04103 Leipzig Germany Phone: +49(0341)48792-40 Fax: +49(0341)48792-39 E-mail: ir@vita34.de Internet: www.vita34.de ISIN: DE000A0BL849 WKN: A0BL84 Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange EQS News ID: 1123793 End of News DGAP News Service